drugset / Trial / NCT02260648

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

NCT02260648

Phase 3 Terminated 149 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib when administered in combination with atorvastatin for 12 weeks in Japanese participants with primary hypercholesterolemia.

Timeline

Start
2015-01
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Evacetrapib Small molecule 130 mg Oral
Comparator Ezetimibe Unknown 10 mg Oral
Background Atorvastatin Small molecule 10 mg Oral

Indications